Premium
Analysis of MicroRNA Expression Profile in PBMCs of Hypertensive Patients
Author(s) -
Pinho Maria Joao,
VazdaSilva Manuel,
SoaresdaSilva Patricio
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.737.3
Subject(s) - microrna , pathogenesis , microarray , gene , gene expression , biology , bioinformatics , downregulation and upregulation , microarray analysis techniques , peripheral blood mononuclear cell , disease , medicine , genetics , immunology , in vitro
MicroRNAs (miRNAs) are endogenous repressors of gene expression and have been reported to play important roles in a number of biological processes. We assessed the miRNA system in Portuguese population of hypertensive subjects in order to investigate the potential of miRNA as biomarkers for essential hypertension (EH). Total RNA was isolated from PBMCs from a total of 66 hypertensive subjects (divided into: group 1, medicated HTA I and II; group 2, medicated HTA III and group 3, nonhypertensive with cardiac disease) and 13 non‐hypertensive subjects. Agilent Human miRNA Microarray 16.0 was used to detect the expression of miRNAs. MiRNA arrays showed that 117, 9 and 21 miRNAs were expressed at different levels in group1, group 2 and group 3, respectively. In addition to several miRNAs previously known to be associated with EH, 4 unidentified miRNA candidates were found to be dysregulated in group 1 samples. Among the novel candidates, the genes hsa‐miR‐4306, hsa‐miR‐146a, hsa‐miR‐146b‐5pn, has‐miR‐22 were upregulated. 14 MiRNAs differentially expressed in group 1 were distributed in 5 miRNA clusters in chromosomes 1, 7, 13 and X. We report four novel miRNA candidates in EH; these miRNA sequences require further validation and functional analysis to evaluate whether they play a role in the pathogenesis of EH. Supported by FCT (PIC/IC/83204/2007)